Literature DB >> 21144838

Construction of a novel expression vector in Pseudonocardia autotrophica and its application to efficient biotransformation of compactin to pravastatin, a specific HMG-CoA reductase inhibitor.

Yoshikazu Fujii1, Koji Norihisa, Tadashi Fujii, Yasuhide Aritoku, Yusuke Kagawa, Khalid Ibrahim Sallam, Osamu Johdo, Akira Arisawa, Tomohiro Tamura.   

Abstract

The novel plasmid vector (pTAOR4-Rev) suitable for gene expression in actinomycete strains of Pseudonocardia autotrophica was constructed from 2 P. autotrophica genetic elements, the novel replication origin and the acetone-inducible promoter. The replication origin was isolated from the endogenous plasmid of strain DSM 43082 and the acetone-inducible promoter was determined by analysis of the upstream region of an acetaldehyde dehydrogenase gene homologue in strain NBRC 12743. P. autotrophica strains transformed with pTAOR4-P450, carrying a gene for cytochrome P450 monooxygenase, expressed P450 from the acetone-inducible promoter, as verified by SDS-PAGE and spectral analysis. The biotransformation test of acetone-induced resting cells prepared from a strain of P. autotrophica carrying pTAOR4 that harbors a compactin (CP)-hydroxylating P450 gene revealed 3.3-fold increased production of pravastatin (PV), a drug for hypercholesterolemia. Biotransformation of CP by the same strain in batch culture yielded PV accumulation of 14.3 g/l after 100 h. The expression vector pTAOR4-Rev and its function-enhancing derivatives provide a versatile approach to industrial biotransformation by Pseudonocardia strains, which can be good hosts for P450 monooxygenase expression. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21144838     DOI: 10.1016/j.bbrc.2010.12.013

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Engineering cytochrome P450 enzyme systems for biomedical and biotechnological applications.

Authors:  Zhong Li; Yuanyuan Jiang; F Peter Guengerich; Li Ma; Shengying Li; Wei Zhang
Journal:  J Biol Chem       Date:  2019-12-06       Impact factor: 5.157

Review 2.  Engineered biosynthesis of natural products in heterologous hosts.

Authors:  Yunzi Luo; Bing-Zhi Li; Duo Liu; Lu Zhang; Yan Chen; Bin Jia; Bo-Xuan Zeng; Huimin Zhao; Ying-Jin Yuan
Journal:  Chem Soc Rev       Date:  2015-05-11       Impact factor: 54.564

3.  Single-step fermentative production of the cholesterol-lowering drug pravastatin via reprogramming of Penicillium chrysogenum.

Authors:  Kirsty J McLean; Marcus Hans; Ben Meijrink; Wibo B van Scheppingen; Aad Vollebregt; Kang Lan Tee; Jan-Metske van der Laan; David Leys; Andrew W Munro; Marco A van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

4.  Strain Improvement of Streptomyces xanthochromogenes RIA 1098 for Enhanced Pravastatin Production at High Compactin Concentrations.

Authors:  Vakhtang V Dzhavakhiya; Tatiana M Voinova; Elena V Glagoleva; Dmitry V Petukhov; Alexander I Ovchinnikov; Maksim I Kartashov; Boris B Kuznetsov; Konstantin G Skryabin
Journal:  Indian J Microbiol       Date:  2015-05-21       Impact factor: 2.461

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.